Share
The Aion International Center for Psychedelic Psychiatry will initially specialise in the use of psilocybin for the treatment of addiction, depression and anxiety
The US Food and Drug Administration (FDA) recently advocated psilocybin therapy as a ‘breakthrough therapy’ for the treatment of major depressive disorder (MDD), which the new Jamaican facility also specialises in. The new centre will also be studying the effectiveness of psilocybin (commonly known as magic mushrooms) as a new therapy for opioid addiction, Alzheimer’s disease, post-traumatic stress disorder (PTSD), and anorexia nervosa.
Dr Winston De La Haye, Medical Director of the Aion International Center for Psychedelic Psychiatry, commented: “We need all available and effective products for the treatment of patients with mental illness. Psychedelic Psychiatry has the potential to change the lives of millions of patients, reducing their disability and improving their quality of life.